If these scenario's come together then Relenza is the last line of defense.
Development of a newly targeted vaccine would have a six month lead time.
I just hope that GSK is ramping up production of the raw material for Relenza very substantially.
The WHO should be demanding it.
The Biota share price is small beer in the face of a significant risk of a virulent 3rd wave resistant to Tamiflu and where the vaccine provides reduced protection.
I am sure that many of the Biota Hot Copperites understand these technical issues and are concerned about the risks - that is why they continue posting because they are concerned about the warning signs.
In contrast there is precious little in the public domain about it. Recombinomics provides a measured interpretation - but is it falling on deaf ears?
Cross your fingers,
Regards Kangaroo1
BTA Price at posting:
$2.14 Sentiment: Hold Disclosure: Held
